Jonathan David Schwartz - 17 May 2024 Form 4 Insider Report for ROCKET PHARMACEUTICALS, INC. (RCKT)

Role
Chief Medical & Gene Therapy Officer
Signature
/s/ Martin Wilson, as attorney-in-fact for Jonathan Schwartz
Issuer symbol
RCKT
Transactions as of
17 May 2024
Net transactions value
-$223,965
Form type
4
Filing time
27 Feb 2025, 16:01:15 UTC
Previous filing
03 Apr 2024
Next filing
13 Feb 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RCKT Common Stock Sale $64,306 -2,754 -1.6% $23.35 169,659 17 May 2024 Direct F1, F2
transaction RCKT Common Stock Sale $50,135 -2,710 -1.6% $18.50 166,949 16 Aug 2024 Direct F1, F2
transaction RCKT Common Stock Sale $40,416 -3,097 -1.9% $13.05 163,852 21 Nov 2024 Direct F1, F2
transaction RCKT Common Stock Sale $69,109 -6,532 -2.7% $10.58 237,638 25 Feb 2025 Direct F1, F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Holdings include Restricted Stock Units ("RSUs") that convert to common stock on a one-for-one basis.
F2 The shares of common stock were sold by the Reporting Person in order to pay tax withholding obligations in connection with the vesting of RSUs.
F3 Inclusive of the acquisition of 80,318 RSUs that convert to common stock on a one-for-one basis, as reported on the Reporting Person's Form 4 filed on 02/13/2025.

Remarks:

Chief Medical & Gene Therapy Officer